EUVIMEDOpdag EUVIMED
Open access

TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine

Anisul Arefin iD, Jihye Kim iD, Manas Pratim Chakraborty iD, Silvia Martinelli iD, Betty Bai, Francis S Lee iD, Joshua Levitz iD

Science Advances · 2026-05-01 · 12 (18)

DOI: 10.1126/sciadv.aec1444 ↗

At a glance

Journal article in Science Advances, published on 2026-05-01. Written by Anisul Arefin and 6 co-authors. Institution: Department of Biochemistry and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA. Major MEDLINE topics: Ketamine, Receptor, Metabotropic Glutamate 5, Receptor, trkB, Neuronal Plasticity. Cited 4 times so far (Crossref); 119 references. The full text is freely available in PubMed Central. Funded by: NIMH NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

A complex ensemble of neuromodulatory receptors orchestrates the many forms of synaptic plasticity that drive behavioral state changes, but an understanding of how such receptors functionally interact is limited. Here, we find that the antidepressant action of ketamine is dependent on both the receptor tyrosine kinase, tropomyosin-related kinase B (TrkB), and the G protein–coupled receptor, metabotropic glutamate receptor 5 (mGluR5). mGluR5 amplifies brain-derived neurotrophic factor (BDNF)–driven signaling of TrkB, enabling synaptic potentiation via “signaling cross-talk,” while BDNF activation of TrkB drives mGluR5 endocytosis via “trafficking cross-talk,” impairing synaptic depression. These modes of cross-talk are enhanced by ketamine, which increases surface and postsynaptic levels of TrkB. Last, we find that an mGluR5 positive allosteric modulator can enhance both modes of cross-talk and boost the effects of ketamine. Together, these data unravel the intimate relationship between different classes of neuromodulatory receptors, revealing that receptor-receptor interplay can drive therapeutic action.

Subjects

MeSH terms (MEDLINE)

KetamineReceptor, Metabotropic Glutamate 5Receptor, trkBNeuronal PlasticityReceptor Cross-TalkSynapsesAnimalsSignal TransductionBrain-Derived Neurotrophic FactorHumans

Substances

KetamineReceptor, Metabotropic Glutamate 5Receptor, trkBBrain-Derived Neurotrophic Factor

Authors and institutions

  • Department of Biochemistry and Biophysics, Weill Cornell Medicine, New York, NY 10065, USA.
  • Department of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA.

ORCID profiles: Anisul Arefin, Jihye Kim, Manas Pratim Chakraborty, Silvia Martinelli, Francis S Lee, Joshua Levitz

Funding

  • NIMH NIH HHS
  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • Burroughs Wellcome Fund
  • Pritzker Neuropsychiatric Disorders Research Consortium
  • The Monique Weil-Caulier Award

Cite

APA

Arefin, A., Kim, J., Chakraborty, M. P., Martinelli, S., Bai, B., Lee, F. S., & Levitz, J. (2026). TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine. Science Advances, 12(18). https://doi.org/10.1126/sciadv.aec1444

Vancouver

Arefin A, Kim J, Chakraborty MP, Martinelli S, Bai B, Lee FS, et al. TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine. Science Advances. 2026;12(18). doi:10.1126/sciadv.aec1444

BibTeX
@article{Arefin2026,
  author = {Arefin, Anisul and Kim, Jihye and Chakraborty, Manas Pratim and Martinelli, Silvia and Bai, Betty and Lee, Francis S and Levitz, Joshua},
  title = {TrkB/mGluR5 cross-talk underlies a synaptic metaplasticity mechanism of ketamine},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {18},
  doi = {10.1126/sciadv.aec1444}
}
Start for free →